Johnson & Johnson (NYSE:JNJ) Shares Acquired by Sugarloaf Wealth Management LLC

Sugarloaf Wealth Management LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.4% in the fourth quarter, Holdings Channel reports. The firm owned 6,576 shares of the company’s stock after buying an additional 397 shares during the quarter. Sugarloaf Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,031,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. King Luther Capital Management Corp boosted its stake in Johnson & Johnson by 0.3% during the 2nd quarter. King Luther Capital Management Corp now owns 643,435 shares of the company’s stock worth $106,501,000 after purchasing an additional 2,027 shares during the period. DORCHESTER WEALTH MANAGEMENT Co raised its position in Johnson & Johnson by 0.6% during the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock worth $11,758,000 after buying an additional 414 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Johnson & Johnson by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 8,843,038 shares of the company’s stock worth $1,463,594,000 after buying an additional 430,445 shares during the last quarter. Cibc World Market Inc. raised its position in Johnson & Johnson by 4.4% during the 2nd quarter. Cibc World Market Inc. now owns 702,435 shares of the company’s stock worth $116,267,000 after buying an additional 29,891 shares during the last quarter. Finally, RAM Investment Partners LLC increased its holdings in shares of Johnson & Johnson by 4.5% in the 4th quarter. RAM Investment Partners LLC now owns 1,688 shares of the company’s stock valued at $265,000 after purchasing an additional 73 shares in the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.20% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $158.18 on Monday. The company has a market cap of $381.02 billion, a PE ratio of 11.45, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The company has a 50-day simple moving average of $159.58 and a 200-day simple moving average of $156.91.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. During the same period in the previous year, the firm earned $2.35 earnings per share. Johnson & Johnson’s revenue was down 9.7% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were issued a $1.19 dividend. The ex-dividend date of this dividend was Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. Johnson & Johnson’s payout ratio is 34.47%.

Analysts Set New Price Targets

Several analysts recently commented on JNJ shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Raymond James raised their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $177.31.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.